Aripiprazole Tablet
Product Images NDC 0904-6656

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 0904-6656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Da814597 50e5 48fa E053 2995a90ab21b 00

aripiprazole 2 mg oral tablets label by Major Pharmaceuticals showing the product name, strength, 500 count package size, storage instructions, pharmacist dispensing note, and distributor and manufacturer information. The label includes dosage instructions, child-resistant closure guidance, and an NDC barcode.*

FDA Label Image

Image Fig1 Effectofotherdrug Arip

A chart titled 'The effects of other drugs on aripiprazole pharmacokinetics' showing aripiprazole fold change and 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0. Various interacting drugs are listed on the y-axis, including CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam) with pharmacokinetic parameters AUC and Cmax indicated.*

FDA Label Image

Image Fig2 Effectofotherdrug Dehydroarip

A chart titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics' showing fold changes and 90% confidence intervals in AUC and Cmax values relative to a reference without interacting drugs. It compares effects of drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam on dehydro-aripiprazole pharmacokinetics.*

FDA Label Image

Image Fig3 Effectofarip Otherdrug

A forest plot chart titled 'The effects of aripiprazole on pharmacokinetics of other drugs' showing fold change and 90% confidence intervals for various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents change relative to reference (without interacting drug), ranging from 0.5 to 3.0. The y-axis lists drugs by metabolic pathway or type, illustrating aripiprazole's impact on their pharmacokinetic parameters such as AUC and Cmax.*

FDA Label Image

Image Fig4 Effectofintrinsicfactor Arip

A figure titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing a chart of aripiprazole fold change with 90% confidence intervals for various special populations including CYP2D6 metabolizer status, gender (female vs. male), age groups (18 to 64 vs. >65 years old), hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment. The chart compares changes in pharmacokinetic parameters AUC and Cmax relative to a reference group.*

FDA Label Image

Image Fig5 Effectofintrinsicfactor Dehydroarip

A pharmacokinetic chart showing the effects of intrinsic factors on dehydro-aripiprazole fold change and 90% confidence intervals. Factors include CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents fold change relative to reference, measuring AUC and Cmax parameters for each comparison.*

FDA Label Image

Image Fig6 Schizophreniastudy 5

Kaplan-Meier plot showing cumulative proportion of patients with relapse over days from randomization in Schizophrenia Study 5, comparing aripiprazole (blue solid line) and placebo (red dashed line). The x-axis displays days from randomization, and the y-axis shows proportion with relapse. A table below the graph lists number of subjects at risk over time for each group.*

FDA Label Image

Image Fig7 Bipolarstudy 7

A Kaplan-Meier curve illustrating the cumulative proportion of patients with relapse in a bipolar study comparing aripiprazole to placebo. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. Two lines represent treatment groups: a solid blue line for aripiprazole and a dashed red line for placebo, with the placebo line showing higher relapse over time.*

FDA Label Image

Image Fig8 Bipolarstudy 8

A Kaplan-Meier survival curve chart showing the cumulative proportion of patients with relapse to any mood event over days from randomization. The chart compares two groups: Abilify (blue solid line) and Placebo (red dashed line), with patients at risk listed below the x-axis at various time points. The y-axis represents the proportion with relapse, ranging from 0 to 1.*

FDA Label Image

Image Fig9 Tourettesdisorderstudy1

A line graph titled 'Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette's Disorder Study 1)' showing change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: ARIP-LOW, ARIP-HIGH, and PLACEBO, with the vertical axis representing change in total tic score and the horizontal axis showing weeks of treatment.*

FDA Label Image

Image Logo Medguide

FDA Label Image

Image Logo Pi

FDA Label Image

Image Structure

Chemical structure of aripiprazole, showing its molecular components including a dichlorophenyl group, piperazine ring, and a quinolinone moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.